SCHEMBL4689596

SCHEMBL4689596

CC(C)=CCCN1C[C@@H]2[C@@H](CNC(=O)C3c4ccccc4Oc4ccccc43)[C@@H]2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 4/20 0.46
MAPT P10636 1/20 0.46
MEN1 O00255 3/20 0.45
LMNA P02545 1/20 0.45
ALDH1A1 P00352 1/20 0.44
ALOX15 P16050 1/20 0.44
POLB P06746 2/20 0.43
NPC1 O15118 1/20 0.42
CCR1 P32246 1/20 0.42
PABPC1 P11940 1/20 0.42
EIF4H Q15056 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4689598 1.00 L3MBTL1 (0.47) L3MBTL1MAPK1KMT2AMAPTMEN1
SCHEMBL4685922 0.86 CCR1 (0.48) L3MBTL1MAPK1KMT2AMAPTMEN1
SCHEMBL4685919 0.86 CCR1 (0.48) L3MBTL1MAPK1KMT2AMAPTMEN1
SCHEMBL4689936 0.84 L3MBTL1 (0.55) L3MBTL1MAPK1KMT2AMAPTMEN1
SCHEMBL4689938 0.84 L3MBTL1 (0.55) L3MBTL1MAPK1KMT2AMAPTMEN1
SCHEMBL13981213 0.82 KMT2A (0.45) KMT2AMAPTMEN1LMNAALDH1A1
SCHEMBL4686638 0.81 LMNA (0.60) L3MBTL1MAPK1KMT2AMAPTMEN1
SCHEMBL4687584 0.81 LMNA (0.60) L3MBTL1MAPK1KMT2AMAPTMEN1
SCHEMBL13989169 0.79 LMNA (0.53) L3MBTL1MAPK1KMT2AMAPTMEN1
SCHEMBL4742808 0.76 MEN1 (0.33) KMT2AMAPTMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765809-B1 XANTHINE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LAB LTD (IN) 2008-12-31 EP claimed
US-20080319002-A1 Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US claimed
EP-1765809-B1 XANTHINE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LAB LTD (IN) 2008-12-31 EP disclosed
US-20080319002-A1 Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US disclosed
US-20080319002-A1 Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US disclosed
US-20080319002-A1 Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists RANBAXY LABORATORIES LIMITED (IN) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319002-A1 Xanthine Derivatives a Useful as Muscarinic Receptor Antagonists CHRM3, CHRM5, CHRM2 L3MBTL1 4395/4885MAPK1 2677/4885KMT2A 3566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.